Lyell Immunopharma (LYEL)
Nasdaq Market Open
Lyell Immunopharma, Inc. is a clinical-stage biotechnology company developing cell therapies designed to treat cancer, with an emphasis on next-generation autologous CAR T-cell candidates. Its work focuses on improving the performance of a patient’s own engineered T cells, a therapeutic approach that has transformed parts of the blood cancer market but remains difficult to apply consistently across more complex tumors.
The company’s lead candidate is rondecabtagene autoleucel, or ronde-cel, also known as LYL314. Ronde-cel is a dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma, a common form of non-Hodgkin lymphoma. By targeting two B-cell antigens, the candidate is intended to address mechanisms of tumor escape that can limit the durability of single-target CAR T therapies.
Lyell also has rights outside mainland China, Hong Kong, Macau and Taiwan to a guanylyl cyclase C, or GCC, targeted CAR T-cell candidate. This program is in early clinical development for refractory metastatic colorectal cancer and other cancers that express GCC, giving the company exposure to solid tumor indications where CAR T success has historically been harder to achieve.
As a listed biotech, Lyell’s valuation is closely tied to clinical data, regulatory progress, manufacturing execution and the competitive landscape in cell therapy. Its pipeline places it in a high-risk, high-potential segment of oncology where scientific differentiation and trial outcomes are central to investor interest.
Last updated
- Market Cap
- 293.31M
- P/E
- —
- P/FCF
- —
- P/S
- 9,461.6
- Enterprise Value
- 202.54M
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Address
- 201 HASKINS WAY, SOUTH SAN FRANCISCO, CA, 94080
Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition
Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series
Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025
Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Advanced Melanoma Clinical Trial Pipeline Analysis - GlobeNewswire
Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
Lyell Immunopharma (LYEL) Is Up 28.45% in One Week: What You Should Know
Lyell Immunopharma Announces Participation in March Investor Conferences
Profound Medical (PROF) Soars 9.4%: Is Further Upside Left in the Stock?
Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference
Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023
Cellares and Lyell to Evaluate Automated Manufacturing of Lyell’s CAR T-Cell Therapy on Cellares’ Cell Shuttle Platform
Lyell Immunopharma to Participate in Upcoming Investor Conferences
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023
Lyell Immunopharma Appoints Matthew Lang as Chief Business Officer
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 293.31M
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 202.54M
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 1.07
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 9,461.6
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -1.12
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 6,533.53
- EPS
- -10.56
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -134.42M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -90.04%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -70.28%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 7.23
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 7.23
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 2.46
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 82.02K
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 12.57
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 2K | 6K | 15K | 8K | 7K |
| Gross profit | 2K | 6K | 15K | 8K | 7K |
| Operating income | -44.26M | -129.79M | -37.25M | -47.14M | -57.37M |
| EBITDA | -41.93M | -61.06M | -34.69M | -42.56M | -53.93M |
| Net income | -24.15M | -140.72M | -38.85M | -42.68M | -52.2M |
| Basic EPS | -1.1 | -7.68 | -2.13 | -2.89 | -3.54 |
| Diluted EPS | -1.1 | -7.68 | -2.13 | -2.89 | -3.54 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 350.63M | 340.05M | 407.97M | 385.45M | 429.8M |
| Total liabilities | 76.96M | 91.85M | 78.84M | 86.53M | 93.28M |
| Total equity | 273.67M | 248.2M | 329.12M | 298.92M | 336.52M |
| Cash & equivalents | 90.77M | 60.18M | 123.58M | 98.8M | 120.33M |
| Current assets | 267.3M | 260.94M | 328.2M | 282.21M | 309.18M |
| Current liabilities | 36.95M | 49.41M | 31.88M | 36.9M | 41.29M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -38.51M | -32.25M | -28.58M | -34.46M | -54.74M |
| Investing cash flow | 17.38M | -31.37M | 3.35M | 12.65M | 69.47M |
| Financing cash flow | 51.72M | 222K | 50M | 183K | 1K |
| Change in cash | 30.59M | -63.39M | 24.77M | -21.63M | 14.73M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | SCHEDULE 13G/A — Lyell Immunopharma, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Lyell Immunopharma, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Lyell Immunopharma, Inc. | View Filing | |
| edgar index | 8-K — Lyell Immunopharma, Inc. | View Filing | |
| edgar index | 10-Q — Lyell Immunopharma, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | DEF 14A — Lyell Immunopharma, Inc. | View Filing | |
| edgar index | DEFA14A — Lyell Immunopharma, Inc. | View Filing | |
| edgar index | ARS — Lyell Immunopharma, Inc. | View Filing | |
| edgar index | SCHEDULE 13G — Lyell Immunopharma, Inc. | View Filing | |
| edgar index | EFFECT — Lyell Immunopharma, Inc. | View Filing | |
| edgar index | CORRESP — Lyell Immunopharma, Inc. | View Filing | |
| edgar index | UPLOAD — Lyell Immunopharma, Inc. | View Filing | |
| edgar index | S-3 — Lyell Immunopharma, Inc. | View Filing | |
| edgar index | 3 — Lyell Immunopharma, Inc. | View Filing | |
| edgar index | 4 — Lyell Immunopharma, Inc. | View Filing | |
| edgar index | S-8 — Lyell Immunopharma, Inc. | View Filing | |
| edgar index | 8-K — Lyell Immunopharma, Inc. | View Filing | |
| edgar index | 10-K — Lyell Immunopharma, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — mda | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | 4 — Lyell Immunopharma, Inc. | View Filing | |
| edgar index | 4 — Lyell Immunopharma, Inc. | View Filing | |
| edgar index | 8-K — Lyell Immunopharma, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — Shah Smital | View Filing | |
| form 4 | Form 4 — BERNS PAUL L | View Filing | |
| form 4 | Form 4 — BYBEE CLINTON | View Filing | |
| form 4 | Form 4 — BERNS PAUL L | View Filing | |
| form 4 | Form 4 — BERNS PAUL L | View Filing | |
| form 4 | Form 4 — ARCH Venture Fund XIII, L.P. | View Filing | |
| form 4 | Form 4 — BYBEE CLINTON | View Filing | |
| form 4 | Form 4 — BYBEE CLINTON | View Filing | |
| form 4 | Form 4 — Burow Kristina | View Filing | |
| form 4 | Form 4 — ARCH Venture Fund XIII, L.P. | View Filing | |
| form 4 | Form 4 — ARCH Venture Fund XIII, L.P. | View Filing | |
| form 4 | Form 4 — Burow Kristina | View Filing | |
| form 4 | Form 4 — Burow Kristina | View Filing | |
| form 4 | Form 4 — NELSEN ROBERT | View Filing | |
| form 4 | Form 4 — ARCH Venture Partners XIII, L.P. | View Filing | |
| form 4 | Form 4 — ARCH Venture Partners XIII, LLC | View Filing | |
| form 4 | Form 4 — CRANDELL KEITH | View Filing | |
| form 4 | Form 4 — GILLIS STEVEN | View Filing | |
| form 4 | Form 4 — NELSEN ROBERT | View Filing | |
| form 4 | Form 4 — NELSEN ROBERT | View Filing | |
| form 4 | Form 4 — ARCH Venture Partners XIII, L.P. | View Filing | |
| form 4 | Form 4 — ARCH Venture Partners XIII, L.P. | View Filing | |
| form 4 | Form 4 — ARCH Venture Partners XIII, LLC | View Filing | |
| form 4 | Form 4 — ARCH Venture Partners XIII, LLC | View Filing | |
| form 4 | Form 4 — CRANDELL KEITH | View Filing | |
| form 4 | Form 4 — GILLIS STEVEN | View Filing | |
| form 4 | Form 4 — CRANDELL KEITH | View Filing | |
| form 4 | Form 4 — GILLIS STEVEN | View Filing | |
| form 4 | Form 4 — ARCH Venture Partners IX, LLC | View Filing | |
| form 4 | Form 4 — ARCH Venture Partners IX, LLC | View Filing | |
| form 4 | Form 4 — ARCH Venture Fund IX, L.P. | View Filing | |
| form 4 | Form 4 — ARCH Venture Partners IX, L.P. | View Filing | |
| form 4 | Form 4 — ARCH Venture Fund IX, L.P. | View Filing | |
| form 4 | Form 4 — ARCH Venture Fund IX, L.P. | View Filing | |
| form 4 | Form 4 — ARCH Venture Partners IX Overage, L.P. | View Filing | |
| form 4 | Form 4 — ARCH Venture Partners IX, L.P. | View Filing | |
| form 4 | Form 4 — ARCH Venture Partners IX, L.P. | View Filing | |
| form 4 | Form 4 — ARCH Venture Partners IX Overage, L.P. | View Filing | |
| form 4 | Form 4 — ARCH Venture Partners IX Overage, L.P. | View Filing | |
| form 4 | Form 4 — ARCH Venture Fund IX Overage, L.P. | View Filing | |
| form 4 | Form 4 — ARCH Venture Fund IX Overage, L.P. | View Filing | |
| form 4 | Form 4 — ARCH Venture Fund IX Overage, L.P. | View Filing | |
| form 4 | Form 4 — ARCH Venture Partners IX, LLC | View Filing | |
| edgar index | 4 — Lyell Immunopharma, Inc. | View Filing | |
| edgar index | 4 — Lyell Immunopharma, Inc. | View Filing | |
| edgar index | 4 — Lyell Immunopharma, Inc. | View Filing | |
| edgar index | 4 — Lyell Immunopharma, Inc. | View Filing | |
| edgar index | 4 — Lyell Immunopharma, Inc. | View Filing |